11 Best Value Stocks to Buy Now

6. GSK (NYSE:GSK)

GSK (NYSE:GSK) is one of the best value stocks to buy now. On February 17, GSK released new real-world evidence showing that its RSV (respiratory syncytial virus) vaccine, Arexvy, is associated with significant reductions in hospitalizations and severe complications among adults aged 60 and older. The data, drawn from a large-scale US study of over 2.5 million people, showed a 75.6% VE (vaccine effectiveness) against RSV-related hospitalization.

Notably, the study also found that the vaccine was associated with a 63.1% reduction in major adverse cardiovascular events, such as heart attacks and strokes, during RSV-related hospital stays. The research also highlighted the vaccine’s impact on underlying respiratory conditions. Among patients with COPD (chronic obstructive pulmonary disease), Arexvy was associated with a 74.4% reduction in severe flare-ups; for those with asthma, the reduction was 61.6%.

A separate nationwide study in Denmark even observed a 100% VE in preventing RSV-related hospitalizations among a specific cohort of COPD patients aged 60 and older. While these observational findings do not prove direct causation, they suggest that vaccination may play a critical role in preventing the cascading health failures often triggered by an RSV infection.

GSK (NYSE:GSK), together with its subsidiaries, researches, develops, and manufactures vaccines, specialty medicines, and general medicines to prevent and treat disease in the UK, the US, and internationally.